Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models

Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models

Abstract Background The development of secondary resistance (SR) in metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (anti-EGFR) antibodies is not fully understood at the molecular level. Here we tested in vivo selection of anti-EGFR SR tumors in CRC patient-der...

Full description

Bibliographic Details
Main Authors: Deepak Vangala, Swetlana Ladigan, Sven T. Liffers, Soha Noseir, Abdelouahid Maghnouj, Tina-Maria Götze, Berlinda Verdoodt, Susanne Klein-Scory, Laura Godfrey, Martina K. Zowada, Mario Huerta, Daniel L. Edelstein, Jaime Martinez de Villarreal, Miriam Marqués, Jörg Kumbrink, Andreas Jung, Tobias Schiergens, Jens Werner, Volker Heinemann, Sebastian Stintzing, Doris Lindoerfer, Ulrich Mansmann, Michael Pohl, Christian Teschendorf, Christiane Bernhardt, Heiner Wolters, Josef Stern, Selami Usta, Richard Viebahn, Jacob Admard, Nicolas Casadei, Stefan Fröhling, Claudia R. Ball, Jens T. Siveke, Hanno Glimm, Andrea Tannapfel, Wolff Schmiegel, Stephan A. Hahn
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Genome Medicine
Subjects:
Anti-EGFR
PDX
Secondary resistance
Targeted treatment
Transcriptional reprogramming
Online Access:https://doi.org/10.1186/s13073-021-00926-7

Internet

https://doi.org/10.1186/s13073-021-00926-7

Similar Items